Market Cap
$8.5B
ABVX
Abivax S.A.
$94.17 ▼ -0.98%
Prev close $95.10Market cap$8.5B
ConsensusStrong Buy
12-mo target$164.00 (+74.1%)
▲ Bullish
Analyst conviction 9/10
High Impact Filing (7/10)27 New Institutional Positions23 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on ABVX right now — valuation, ownership and activity at a glance.
Cap Size
Mid Cap
Analyst Consensus
Strong Buy (86%)
Inst. Holders
50 funds
Inst. Value
$3.6B
Inst. Activity
27 buys / 23 sells
Social Sentiment
67° Warm
SEC Reports
5
Press Releases
3
Price chart 30d -15.2%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 30, 2026 other
Aug 6, 2026 SEC Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026
Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026
Four institutional investors doubled their ABVX positions in Q2 2026, led by Pictet Asset Management ($54.4M increase) a
INST-CLUSTER — Impact 5/10
Abivax is raising approximately $759.8 million in net proceeds through a public offering of 6,400,000 ADSs at $125.00 pe
424B5 — Impact 6/10
Abivax SA filed a 6-K on July 2, 2026, disclosing the entry into an underwriting agreement for a public offering of 6,40
6-K — Impact 6/10
Abivax priced an upsized $800M public offering of 6.4M ADSs at $125 per ADS, a 2.4% premium to VWAP, representing 8% dil
Impact 6/10
Jun 30, 2026 Inst.
UBS Group AG — TRIM
1,844,918 shares ($245.9M)
Jun 30, 2026 Inst.
Jun 29, 2026 Press CITADEL ADVISORS LLC — DOUBLED
1,438,352 shares ($191.7M)
Abivax reported positive topline results from ABTECT Maintenance Part 2 for obefazimod in refractory ulcerative colitis,
Impact 7/10
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
86% rate it Buy or better · 14 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 22, 2026 | Truist Securities | MAINTAIN | Buy | 55% |
| Sep 22, 2026 | Wedbush | MAINTAIN | Neutral | 57% |
| Sep 22, 2026 | Barclays | MAINTAIN | Overweight | 54% |
| Sep 10, 2026 | Goldman Sachs | INITIATE | Buy | 54% |
| Sep 5, 2026 | BTIG | REITERATE | Buy | 53% |
| Jul 9, 2026 | Piper Sandler | MAINTAIN | Overweight | 54% |
| Jul 2, 2026 | Truist Securities | MAINTAIN | Buy | 55% |
| Jul 1, 2026 | Citizens | REITERATE | Market Outperform | 38% |
| Jun 30, 2026 | Jefferies | UPGRADE | Buy | 53% |
| Jun 30, 2026 | Leerink Partners | MAINTAIN | Outperform | 49% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 6 | 6 | 2 | 0 | 0 | 86% | |
| Aug 1, 2026 | 6 | 6 | 2 | 0 | 0 | 86% | |
| Jul 1, 2026 | 6 | 6 | 2 | 0 | 0 | 86% | |
| Jun 1, 2026 | 6 | 6 | 2 | 0 | 0 | 86% | |
| May 1, 2026 | 6 | 6 | 2 | 0 | 0 | 86% | |
| Apr 1, 2026 | 6 | 6 | 2 | 0 | 0 | 86% | |
| Mar 1, 2026 | 6 | 6 | 2 | 0 | 0 | 86% | |
| Feb 1, 2026 | 6 | 6 | 2 | 0 | 0 | 86% |
Price targets
Where 12 covering analysts think ABVX trades over the next 12 months.
$164.00 +74.1% upside Strong Buy
Current$94.17 Low$142.00 Median$164.00 High$181.00 12 analysts
$142.00$181.00
Analyst rating Strong Buy· 1.3/5 as of Oct 2, 2026
Social media sentiment mood +0.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
67°
Warm
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
5 SEC filing reports analyzed · 1 bullish, 2 bearish, 1 mixed, 1 neutral · avg impact 5.8/10.Plus 3 press releases.
MIXEDINST-CLUSTER5/10
Four institutional investors doubled their ABVX positions in Q2 2026, led by Pictet Asset Management
Aug 6, 2026
BEARISH424B56/10
Abivax is raising approximately $759.8 million in net proceeds through a public offering of 6,400,00
Jul 3, 2026
BEARISH6-K6/10
Abivax SA filed a 6-K on July 2, 2026, disclosing the entry into an underwriting agreement for a pub
Jul 3, 2026
BULLISH6-K7/10
Abivax reported positive topline results from Part 2 of the Phase 3 ABTECT maintenance trial for obe
Jun 29, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 30, 2026
other
Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026
Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026
Sep 29, 2026
Clinical Trial
ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma
Phase Phase 2 — COMPLETED
Sep 21, 2026
other
Abivax Presents Business Updates and First Half 2026 Financial Results
Abivax Presents Business Updates and First Half 2026 Financial Results
Sep 10, 2026
Clinical Trial
ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2
Phase Phase 3 — COMPLETED
Sep 10, 2026
Clinical Trial
ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1
Phase Phase 3 — COMPLETED
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.90 | $-1.11–$-0.61 | 63.5% | -34.2% | 2↑ 0↓ | $0.0B | 4 |
| Next Q | $-0.90 | $-1.16–$-0.65 | 24.0% | -16.3% | 2↑ 1↓ | $0.0B | 4 |
| Current FY | $-4.24 | $-4.67–$-3.89 | 24.2% | -18.3% | 6↑ 0↓ | $0.0B | 6 |
| Next FY | $-3.88 | $-4.91–$-2.58 | 8.5% | -23.4% | 6↑ 0↓ | $0.1B | 7 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.902 | — |
| 7d ago | $-0.763 | -0.139 |
| 30d ago | $-0.673 | -0.230 |
| 60d ago | $-0.673 | -0.230 |
| 90d ago | $-0.712 | -0.191 |
Institutional ownership
Which big funds own ABVX (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $3.6B total value (27,398,254 shares) as of 2026-Q2. Top holders: Clear, SUSQUEHANNA, Jupiter. Net buying activity: 27 institutions added/increased vs 23 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| Clear Street Group Inc. | 3,811 | $0.00 | 0.0% | — |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 2,458,800 | $327.7M | 9.0% | DOUBLED +176.4% |
| Jupiter Topco LLC | 1,913,933 | $255.1M | 7.0% | — |
| UBS Group AG | 1,844,918 | $245.9M | 6.7% | TRIM -59.4% |
| CITADEL ADVISORS LLC | 1,604,800 | $213.9M | 5.9% | DOUBLED +164.2% |
| CITADEL ADVISORS LLC | 1,438,352 | $191.7M | 5.3% | DOUBLED +164.2% |
| MORGAN STANLEY | 1,432,185 | $190.9M | 5.2% | — |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 1,309,825 | $174.5M | 4.8% | — |
| CITADEL ADVISORS LLC | 1,200,600 | $160.0M | 4.4% | DOUBLED +164.2% |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1,135,200 | $151.3M | 4.1% | DOUBLED +176.4% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| UBS Group AG | TRIM | 4,547,406 | 1,844,918 | -59.4% | $245.9M |
| CITADEL ADVISORS LLC | DOUBLED | 544,338 | 1,438,352 | +164.2% | $191.7M |
| RA CAPITAL MANAGEMENT, L.P. | NEW | — | 1,132,557 | — | $150.9M |
| NORGES BANK | NEW | — | 1,100,000 | — | $146.6M |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | DOUBLED | 381,282 | 1,053,896 | +176.4% | $140.4M |
| BANK OF AMERICA CORP /DE/ | ADD | 735,729 | 971,439 | +32.0% | $129.5M |
| GOLDMAN SACHS GROUP INC | DOUBLED | 348,797 | 792,712 | +127.3% | $105.6M |
| BALYASNY ASSET MANAGEMENT L.P. | DOUBLED | 213,689 | 603,840 | +182.6% | $80.5M |
| BlackRock, Inc. | ADD | 427,335 | 574,061 | +34.3% | $76.5M |
| Pictet Asset Management Holding SA | DOUBLED | 103,545 | 492,068 | +375.2% | $65.6M |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for ABVX.
Shares short
6,858,511
Settlement Sep 15, 2026
Change vs prior
-1.5%
Semi-monthly cycle
Days to cover
6.2
At avg daily volume
Of shares outstanding
≈8.0%
Estimate — not % of float
All ABVX filing & press-release reports (8)
- INST-CLUSTER reportAug 6, 2026
- 424B5 reportJul 3, 2026
- 6-K reportJul 3, 2026
- PRESS-RELEASE reportJul 1, 2026
- 6-K reportJun 29, 2026
- PRESS-RELEASE reportJun 29, 2026
- PRESS-RELEASE reportMay 22, 2026
- PRESS-RELEASE reportMar 23, 2026